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Introduction {#sec001}
============

Cardiometabolic diseases are at the forefront of comorbidities in the Chronic Obstructive Pulmonary Disease (COPD) population \[[@pone.0231072.ref001]\]. It has been reported that individuals with COPD have a 2- to 5-time higher risk of cardiovascular disease compared with controls, independently of shared risk factors such as age and smoking \[[@pone.0231072.ref002],[@pone.0231072.ref003]\]. Understanding the nature of the link between COPD and co-existing metabolic conditions/comorbidities may provide personalized treatment strategies and identify new mechanistic pathways to be targeted.

The relationship between COPD and its comorbidities is complex and studies having reported a high prevalence of metabolic syndrome and obesity in patients with COPD \[[@pone.0231072.ref004]--[@pone.0231072.ref007]\] have suggested the existence of pathophysiological links between hypertriglyceridemia and hypoxia \[[@pone.0231072.ref008],[@pone.0231072.ref009]\], obesity and hypoxia \[[@pone.0231072.ref010]--[@pone.0231072.ref012]\], or visceral adiposity and pulmonary function \[[@pone.0231072.ref013]--[@pone.0231072.ref016]\]. Various phenotypes of COPD have emerged, some of which being defined by the adiposity and metabolic profile of the patients \[[@pone.0231072.ref017]--[@pone.0231072.ref020]\]. In a previous investigation \[[@pone.0231072.ref021]\], we found that the degree of visceral adiposity with its associated hypertension and diabetes correlated with the severity of COPD \[Global initiative for Obstructive Lung Disease (GOLD) grade\]. Several potential confounders (tobacco exposure, dietary habits, sedentarity) may, however, complicate the establishment of a link between COPD and metabolic abnormalities.

In the present investigation based on the above-mentioned cohort, we aimed to further explore whether COPD is linked to established metabolic variables (insulin resistance \[[@pone.0231072.ref022]--[@pone.0231072.ref026]\], lipid control \[[@pone.0231072.ref027]\] and visceral adiposity \[[@pone.0231072.ref028],[@pone.0231072.ref029]\]) in a well-phenotyped cohort representative of the general population. We hypothesized that if there is causal and self-sustaining links between COPD and metabolic abnormalities, then differences in metabolic risk factors should emerge between individuals with COPD and control subjects. The present study was embedded in the Canadian Cohort Obstructive Lung Disease Study (CanCOLD), a prospective longitudinal study of COPD with random population sampling \[[@pone.0231072.ref030]\].

Methods {#sec002}
=======

Participants {#sec003}
------------

The study was approved by the local ethics committee (Comité d'éthique du centre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, IRB N° 20690, Study N° 2012--1359). CanCOLD (ClinicalTrials.gov: NCT00920348) steering and scientific committees approved the sub-study protocol. All study participants signed written consent before inclusion.

Participants in two CanCOLD study centres (Montreal and Quebec City, Quebec, Canada) were recruited between February 2012 and December 2015 for this sub-study. CanCOLD is a longitudinal cohort study based on the characterization of COPD among a random sample of the population in 9 Canadian cities \[[@pone.0231072.ref030]\]. Subjects had to be 40 years or older to participate in the CanCOLD study. Further details concerning the CanCOLD study design and eligibility criteria have been previously described \[[@pone.0231072.ref030]\]. Study participants underwent the standard CanCOLD assessment procedures, which provide information about patients' characteristics (age, gender, smoking history), medical history and current medications, body weight and height, and pulmonary function. Although no sleep studies were done in CanCOLD, the presence of sleep apnea was documented based on the use of continuous airway positive pressure (CPAP) and on standardized questionnaires, including the Pittsburg Sleep Quality Index \[[@pone.0231072.ref031]\]. Additional pre-specified measures were done including measurements of waist and hip circumferences, blood sampling to determine glucose and lipid profiles, and a computed tomography (CT) abdominal scan at 4^th^/5^th^ lumbar vertebrae level (L4-L5) to quantify body fat distribution \[[@pone.0231072.ref021]\]. Participants were divided according to the pulmonary function testing results as follows: 1) control subjects with a post-bronchodilator forced expiratory volume in 1 second (FEV~1~) \> 80% predicted value and FEV~1~/forced vital capacity (FVC) ratio \> 0.7; 2) patients with COPD with a post-bronchodilator FEV~1~/FVC ratio \< 0.7 were further classified according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) airflow limitation classification scheme into GOLD 1, with an FEV~1~ ≥ 80% predicted, and GOLD 2+ with an FEV~1~\<80% predicted. All COPD subjects were invited to be enrolled in the final CanCOLD cohort, whereas some of the healthy subjects were enrolled to serve as controls with a control/COPD ratio of 1 to 1 \[[@pone.0231072.ref030]\]. Patients with a pulmonary restrictive profile were excluded from the analysis.

Procedures {#sec004}
----------

### Body fat distribution and visceral adipose tissue assessment {#sec005}

L4-L5 CT scan images were analyzed without knowledge of the clinical status of the subjects. Abdominal fat distribution was assessed using the specialized software Tomovision SliceOMatic (v4.3 Rev-6f, Montreal, Quebec, Canada). The detailed method used for image analysis has been previously reported \[[@pone.0231072.ref032], [@pone.0231072.ref033]\]. The middle of the muscle wall surrounding the abdominal cavity was delineated to determine the visceral adipose tissue (VAT) area. Abdominal adipose tissue areas were computed using an attenuation range of --190 to --30 Hounsfield units (HU). Body fat distribution parameters were obtained with methodology commonly applied in our Core Lab, with high levels of intra and inter-observer agreement \[[@pone.0231072.ref032]\].

### Blood sample and biochemical analysis {#sec006}

Blood samples were collected in the morning, after a 12-hour fast to determine levels of glucose, insulin, total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides. All analyses were carried-out in plasma or whole blood using automated techniques (Roche Diagnostics). Glucose, total cholesterol (TC), HDL-cholesterol, LDL-cholesterol, and triglycerides were measured by enzymatic *in vitro* tests. Insulin was determined using electrochemiluminescence immunoassay (ECLIA). Insulin resistance was assessed using the homeostatic model assessment for insulin resistance (HOMA-IR), calculated using the following formula: insulinemia × glucose/22.5 (glucose units mmol/L) \[[@pone.0231072.ref034]\].

Data analysis {#sec007}
-------------

Continuous data are presented as median and interquartile range (IQR) or mean and 95% confidence interval in case of normal distribution, and categorical data as frequency and percentage. Continuous variables were analysed using a Mann-Whitney test and categorical data and proportions were analysed using the Fisher exact tests. Metabolic phenotypes were compared between COPD and controls by using four complementary strategies: 1) univariate comparisons of adiposity and metabolic parameters (triglycerides, total/HDL cholesterol ratio, and HOMA-IR) between COPD subjects, GOLD 1 subjects, GOLD 2+ subjects and controls (Mann-Whitney test); 2) univariate linear regression with coefficient of determination (R^2^) and analysis of covariance (ANCOVA) to study the relationships between metabolic parameters (triglycerides, total/HDL cholesterol ratio, HOMA-IR) and indices of adiposity (body mass index (BMI), waist-to-hip ratio and VAT area) according to COPD status; 3) multivariate linear regression models to detect possible interactions between the COPD status and the various metabolic parameters studied. A logarithmic transformation (Ln) was performed on each non-log-linear variable of interest. These models took into consideration (variable entry) all potential confounders available, including age, sex, smoking status, BMI, waist-to-hip ratio, corticosteroid treatment, hypolipidemic and hypoglycemic agents. Final models were selected with backwards elimination, with COPD status as a forced variable and keeping only the significant variables at *p* \<0.05; and 4) multivariate logistic regressions to estimate the odds ratio of having hypertriglyceridemia (triglyceride \>1.5 mmol/L), increased total /HDL cholesterol ratio\>4 \[[@pone.0231072.ref035]\], and insulin resistance (HOMA-IR\>3) \[[@pone.0231072.ref022]--[@pone.0231072.ref026]\] in the presence of COPD (all COPD and COPD GOLD2+ only) compared to non-COPD controls. These models were adjusted for potential confounders (age, sex, smoking status, BMI, corticosteroid treatment and ongoing pharmacological treatment related to the parameter studied, namely hypolipidemic drugs or hypoglycemic drugs). The odds ratio of having visceral obesity (L4-L5 VAT cross-sectional area \>75^th^ percentile of the whole population by sex) in the presence of COPD (all COPD and COPD GOLD2+ only) in comparison to non-COPD controls was analysed by multivariate logistic regression including age, smoking status and inhaled corticosteroid treatment as known confounding factors. In these multivariate logistic regressions, continuous variables were entered as quartiles. Missing data were not replaced. All statistical analyses were performed using IBM SPSS v.23 software (IBM statistics, USA) and GraphPad Prism v6.05 (GraphPad Software, USA).

Results {#sec008}
=======

This CanCOLD sub-study included 263 participants having a median age of 65 \[59--71\] years and of whom two thirds were males. Based on pulmonary lung function, subjects were divided into control subjects with normal lung function (n = 119), and individuals with COPD (n = 144, 70 GOLD 1 and 74 GOLD 2+). No missing data in variables of interest have to be reported. There was no statistically significant between-group difference for age, sex, BMI, waist-to-hip ratio, and use of hypolipidemic and oral hypoglycemic agents (**[Table 1](#pone.0231072.t001){ref-type="table"}**).

10.1371/journal.pone.0231072.t001

###### Baseline characteristics by group.

![](pone.0231072.t001){#pone.0231072.t001g}

                                      Control subjects (n = 119)   COPD (n = 144)        P value
  ----------------------------------- ---------------------------- --------------------- ---------
  Age, years                          65 \[59--71\]                65 \[59--71\]         0.88
  Male, n (%)                         73 (61.3)                    93 (64.6)             0.61
  BMI, kg/m^2^                        26.5 \[23.5--29.7\]          26.6 \[23.7--29.4\]   0.96
  Waist-to-hip ratio, mean (95% CI)   0.93 (0.92--0.94)            0.94 (0.93--0.95)     0.14
  Waist circumference, cm             96 \[87.8--103\]             98 \[89--106\]        0.20
  Current smokers, n (%)              12 (10.1)                    39 (27.1)             \<0.001
  Former smokers, n (%)               70 (58.8)                    74 (51.4)             0.26
  Never smokers, n (%)                37 (31.1)                    31 (21.5)             0.09
  Pack/year                           11 \[0--28\]                 27 \[0--50\]          \<0.001
  **Comorbidities**                                                                      
  Hypertension, n (%)                 32 (26.9)                    53 (36.8)             0.11
  Diabetes, n (%)                     10 (8.4)                     14 (9.7)              0.83
  Dyslipidemia, n (%)                 31 (26.1)                    41 (28.5)             0.68
  Coronary artery disease, n (%)      6 (5.0)                      14 (9.7)              0.17
  Stroke, n (%)                       1 (0.8)                      9 (6.3)               0.02
  Sleep apnea, n (%)                  4 (3.4)                      9 (6.3)               0.39
  **Pulmonary Function, post BD**                                                        
  FEV~1~, L                           2.88 \[2.37--3.48\]          2.14 \[1.55--2.99\]   \<0.001
  FEV~1~, % predicted                 101 \[92--110\]              79 \[65--93\]         \<0.001
  FVC, L                              3.79 \[3.09--4.52\]          3.63 \[2.75--4.69\]   0.48
  FVC, % predicted                    120 \[112--132\]             118 \[103--135\]      0.21
  FEV~1~/FVC, %                       76.8 \[73.4--79.9\]          62.3 \[55.7--66.5\]   \<0.001
  PEF, mean L/sec (95% CI)            7.42 (6.98--7.86)            7.42 (7.02--7.82)     \<0.001
  FEF 25--75, L/sec                   1.60 \[0.96--2.41\]          1.58 \[0.95--2.41\]   \<0.001
  GOLD 1, n (%)                       \-                           70 (48.6)             \-
  GOLD 2, n (%)                       \-                           61 (42.4)             \-
  GOLD 3--4, n (%)                    \-                           13 (9.0)              \-
  GOLD A, n (%)                       \-                           91 (63.2)             \-
  GOLD B, n (%)                       \-                           40 (27.8)             \-
  GOLD C, n (%)                       \-                           3 (2.1)               \-
  GOLD D, n (%)                       \-                           10 (6.9)              \-
  **Medications at baseline**                                                            
  Short-acting BD, n (%)              2 (1.7)                      24 (16.6)             \<0.001
  Long-acting BD, n (%)               1 (0.8)                      1 (0.7)               1
  Inhaled CS, n (%)                   3 (0.3)                      33 (22.9)             \<0.001
  Statins, n (%)                      28 (23.5)                    38 (26.4)             0.67
  Other hypolipidemic drugs, n (%)    4 (3.3)                      3 (2.1)               0.70
  Insulin, n (%)                      1 (0.8)                      0 (0)                 0.45
  Oral hypoglycemic agents, n (%)     9 (7.6)                      10 (6.9)              1

Values are median \[IQR\] if not stated otherwise. COPD: chronic obstructive pulmonary disease; BMI: body mass index; CI: confidence interval; BD: bronchodilator; FEV~1~: forced expiratory volume in 1 second; FVC: forced vital capacity; BD: bronchodilator; CS: corticosteroids; GOLD: global Initiative for obstructive lung disease classification.

Metabolic profiles according to COPD status are provided in **[Fig 1](#pone.0231072.g001){ref-type="fig"}**. There was no significant difference between groups in triglyceride levels (**[Fig 1A](#pone.0231072.g001){ref-type="fig"}**), total/HDL cholesterol ratio (**[Fig 1B](#pone.0231072.g001){ref-type="fig"}**), and insulin resistance (HOMA-IR) (**[Fig 1C](#pone.0231072.g001){ref-type="fig"}**). The median VAT levels in control subjects (146.4 cm^2^ \[106.2--222.6\]) was not different compared to COPD subjects (155.7 cm^2^ \[108.9--233.9\], *p* = 0.59), and to GOLD 1 or GOLD 2+ COPD (**[Fig 1D](#pone.0231072.g001){ref-type="fig"}**). No significant difference was observed between COPD and controls in univariate analysis stratified by BMI for any metabolic parameter (**[S1 Fig](#pone.0231072.s009){ref-type="supplementary-material"}**).

![Metabolic parameters according COPD status.\
COPD: chronic obstructive pulmonary disease; HDL: high density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance; VAT CSA: visceral adipose tissue cross-sectional area on L4-L5. p\>0.05 for all between-group comparisons.](pone.0231072.g001){#pone.0231072.g001}

Triglycerides, total/HDL cholesterol ratio and HOMA-IR were positively associated with the three indices of adiposity (BMI, waist-to-hip ratio and VAT area) in individuals with COPD and controls. (**[Fig 2](#pone.0231072.g002){ref-type="fig"}**, all regression lines with a p\<0.05). However, the slopes of the regression lines were similar for both groups (p\>0.05 for all comparisons) suggesting that the relationships between metabolic markers and adiposity were not modified in the presence of COPD.

![Relationships between metabolic parameters and BMI, waist-to-hip ratio and VAT CSA in individuals with COPD and controls.\
COPD: chronic obstructive pulmonary disease; BMI: body mass index; HDL: high density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance; VAT CSA: visceral adipose tissue cross-sectionnal area on L4-L5. All coefficients of determination (R^2^) are\<0.3; All regression line slopes were significantly different from 0 (p\<0.05); however, none of the regression lines couples (COPD vs. controls) were significantly different (p\>0.05 for all comparisons).](pone.0231072.g002){#pone.0231072.g002}

In linear multivariate analyses, the COPD status was not significantly associated with triglyceride levels, total/HDL cholesterol, insulin resistance (HOMA-IR) or VAT area (**[Table 2](#pone.0231072.t002){ref-type="table"}**). A higher BMI was associated with an increase in triglycerides, total/HDL cholesterol, and HOMA-IR levels, and current smokers with one third of additional VAT. No significant interaction was observed between the COPD status and any characteristic tested.

10.1371/journal.pone.0231072.t002

###### Multivariate linear regression models.

![](pone.0231072.t002){#pone.0231072.t002g}

                              Effect (%) [^\#^](#t002fn002){ref-type="table-fn"}   p*-*value
  --------------------------- ---------------------------------------------------- -------------
  **Triglycerides**                                                                
  COPD                        +5.5                                                 0.262
  Age (years)                 **-0.6**                                             **0.029**
  BMI Kg/m^2^                 **+3.8**                                             **\<0.001**
  **Total/HDL cholesterol**                                                        
  COPD                        +1.2                                                 0.721
  Sex (men)                   **+10.3**                                            **0.005**
  BMI Kg/m^2^                 **+2.3**                                             **\<0.001**
  Hypolipidemic (yes)         **-18.0**                                            **\<0.001**
  **HOMA-IR**                                                                      
  COPD                        -1.8                                                 0.858
  Sex (men)                   **+27.0**                                            **0.020**
  BMI Kg/m^2^                 **+12.0**                                            **\<0.001**
  **VAT CSA**                                                                      
  COPD                        +1.1                                                 0.866
  Age (years)                 **+1.0**                                             **0.007**
  Sex (men)                   **+14.7**                                            **0.047**
  Current smoker (yes)        **-32.6**                                            **\<0.001**
  Pack-years (n)              **+0.7**                                             **\<0.001**

Significant p-values are shown in bold.

\#: effect on variable in %, per increase in variable. COPD: chronic obstructive pulmonary disease; BMI: body mass index; HDL: High Density Lipoprotein; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; VAT CSA: Visceral Adipose Tissue Cross-sectionnal Area. Only significant factors and COPD are kept in the model by a backward selection.

Lastly, a triglyceride level above 1.5 mmol/L, a total/HDL cholesterol ratio above 4 or a HOMA-IR above 3 were respectively observed in 54 (37.5%), 36 (25%) and 58 (40.3%) of COPD patients and in 37 (31.1%), 33 (27.7%) and 54 (45.4%) of control subjects. In multivariate analysis, the COPD status (or COPD 2+) was not associated with triglyceride \>1.5 mmol/L, total/HDL cholesterol ratio \>4, HOMA-IR\>3, or VAT area\>75^th^ percentile. Only the COPD 2+ status was associated with a VAT area\>75^th^ percentile (OR = 2.27, CI95% 1.00; 5.15, p = 0.05). Complete regression models are available in supplementary [S1](#pone.0231072.s001){ref-type="supplementary-material"}--[S8](#pone.0231072.s008){ref-type="supplementary-material"} Tables.

Discussion {#sec009}
==========

In a population-based cohort consisting of individuals with mild to moderate COPD and control subjects, we found metabolic profiles (lipid profile, HOMA-IR, and VAT accumulation) that were not influenced by the presence of COPD. The well-established relationships between triglycerides, total/HDL cholesterol ratio, and HOMA-IR to indices of adiposity \[[@pone.0231072.ref036],[@pone.0231072.ref037]\], which were confirmed here, were not modified in the presence of COPD. Univariate and multivariate analyses showed an absence of association between COPD and metabolic disorders or visceral adiposity. Therefore, based on this thorough statistical approach, we conclude that COPD does not emerge as an independent risk factor for metabolic disorders and visceral adiposity in a cohort that can be considered representative of the entire population.

Numerous studies have explored possible physiopathological links between COPD, asthma or sleep apnea and cardiometabolic components \[[@pone.0231072.ref038]\]. In those respiratory diseases, several bidirectional mechanisms have been proposed to enhance the risk of hypertriglyceridemia, adipose tissue accumulation and insulin resistance, including hypoxia \[[@pone.0231072.ref008]--[@pone.0231072.ref012]\] and hypercapnia \[[@pone.0231072.ref039]\]. Activation of lipolysis in adipose tissue in the presence of hypoxia led to the \"adipose tissue hypoxia\" concept \[[@pone.0231072.ref011]\]. Adipose tissue would then appear to play a central role in the development of chronic inflammation, macrophage infiltration, and would also be responsible for increasing circulating free fatty acids \[[@pone.0231072.ref008],[@pone.0231072.ref010],[@pone.0231072.ref011]\]. In addition, fat-induced systemic inflammation involving adipokines \[[@pone.0231072.ref038],[@pone.0231072.ref040]--[@pone.0231072.ref042]\], insulin and its receptor, has been implicated in lung injury and airway responsiveness \[[@pone.0231072.ref038],[@pone.0231072.ref043],[@pone.0231072.ref044]\], causing a deleterious pathophysiological loop.

In light of the above potential pathophysiological links between chronic respiratory diseases and cardiometabolic risk factors, it was deemed legitimate to propose that COPD may contribute to the development of metabolic abnormalities. In one of the most large-scale studies in the field, Leone et al. \[[@pone.0231072.ref013]\] found an association between lung function impairment and "classical" components of the metabolic syndrome. This result was obtained in a heterogeneous population (obstructive and restrictive ventilatory defects), and a sub-analysis restricted to individuals with an obstructive ventilatory defect failed to find an association between glucose or lipid levels and lung function impairment, in line with our present results as well as previous ones \[[@pone.0231072.ref045],[@pone.0231072.ref046]\].

The phenotypic heterogeneity of COPD patients and many confounding factors must be considered when comparing the interaction between COPD and metabolic variables across studies. The prevalence of obesity in COPD is highly variable between studies and countries \[[@pone.0231072.ref047]\]. Some populations showed higher prevalence of obesity \[[@pone.0231072.ref048]\] with an over-representation in patients with moderate airflow limitation \[[@pone.0231072.ref049],[@pone.0231072.ref050]\], whereas in the worldwide population-based BOLD study \[[@pone.0231072.ref047]\], obesity was less frequent in COPD than in non-COPD. The importance of BMI as a confounding factor in the observed link between COPD and metabolic parameters is clearly illustrated in our data (**[S1 Fig](#pone.0231072.s009){ref-type="supplementary-material"}**, **[Table 2](#pone.0231072.t002){ref-type="table"}**). In multivariate analyses, BMI was the factor with the strongest association with the metabolic parameters studied. In the same way, treatment with inhaled corticosteroids (present in only 23% of our COPD subjects) could also confound the relationship between COPD, metabolism and adipose tissue accumulation. Inhaled corticosteroids have been related to a 3-fold increase in the likelihood of having a VAT \> 75^th^ percentile (**[S7 Table](#pone.0231072.s007){ref-type="supplementary-material"}**). Based on these considerations, it becomes obvious that differences in population phenotypes across studies could at least partially account for inconsistent conclusions about COPD being a risk factor for altered metabolic status \[[@pone.0231072.ref005]\]. In this regard, data obtained from clinical cohorts are unlikely to be generalizable to the populational level where the majority of patients has only mild to moderate COPD.

Our study has some limitations. First, given the relatively small sample size, a lack of statistical power could be proposed to explain the absence of differences in endpoints between COPD subjects and controls. However, the similitude in the distribution of metabolic variables and obesity in the two groups studied makes this explanation unlikely. Second, the relatively small size of our otherwise well phenotyped sample could have led to a lesser representative image of the population than did the entire CanCOLD cohort. Despite this, the distribution of study participants' characteristics in this sub-study was very similar to that of the entire cohort \[[@pone.0231072.ref051]\], with a majority of subjects with GOLD 1 and few GOLD 3 and 4 COPD. Furthermore, only 30% of individuals with COPD in this sub-study were previously diagnosed with the disease, another similitude with other population-based cohorts \[[@pone.0231072.ref052]\], providing further reassurance regarding how representative the present cohort is of the general population. That said, despite all the care devoted to building a cohort of individuals representative of the general population, some biases may still be present. For example, the most fragile or diseased subjects would probably be less inclined to participate in a clinical study. Third, focusing on a representative and occidental population of COPD, our findings do not necessarily apply to individuals with severe COPD or to those exhibiting particular phenotypes (inflammatory, underweight or obese, with preponderant vascular comorbidities). Finally, physical activity, an important confounder for cardiovascular risk, was not included in the analysis; also, sleep apnea, another potential contributor, was underdiagnosed by far in this cohort when considering the reported prevalence.

Conclusions {#sec010}
===========

In our cohort randomly drawn from the general population in which individuals with COPD mostly had mild-to-moderate airflow limitation, no difference in the distribution of metabolic parameters appeared compared to control subjects. As such, COPD did not emerge as a specific risk factor for metabolic disorders or visceral adiposity. Although a strong mechanistic rationale can be developed for the existence of physiopathological links between chronic respiratory diseases and dyslipidemia, insulin resistance or visceral adiposity, their existence is likely restricted to specific phenotypes or to the most severely affected patients who are not widely represented in the general population.
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Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Qinghua Sun, MD, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2.. Thank you for including your ethics statement:

\'All patients provided written informed consent and the study were approved by ethics

committees of participating centres. CanCOLD (ClinicalTrials.gov: NCT00920348)

steering and scientific committees approved the sub study protocol\'

Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research>.

3\. Please provide additional details regarding healthy participants consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was suitably informed and (2) what type you obtained (for instance, written or verbal). If your study included minors under age 18, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

4\. We noticed you have some minor occurrence(s) of overlapping text with the following previous publication(s), which needs to be addressed:

<https://doi.org/10.2147/COPD.S168963>

<https://doi.org/10.1152/ajpendo.00505.2018>

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed.

5\. One of the noted authors is a group or consortium CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.

6\.

Thank you for stating the following in the Competing Interests section:

\"The authors have declared that no competing interests exist\"

We note that you received funding from a commercial source: Astra Zeneca Canada Ltd; Boehringer Ingelheim Canada Ltd; GlaxoSmithKline Canada Ltd; Novartis; Almirall; Merck Nycomed; Pfizer Canada Ltd; and Theratechnologies.

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other [relevant declarations](http://www.plosone.org/static/competing.action) relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This article tries to find out if COPD contributes independently to development of some cardiometabolic risk factors (visceral adipose tissue, assessment of insulin resistance: HOMA-IR and lipids profile).

Major points:

1\) The study was with random population sampling, and at last it included 263 participants. As indicated in the limitations, it could be a small sample size. Is this sample representative of the general population? Why did you do only a sub-analysis restricted to individuals with an obstructive ventilatory defect?

2\) In the results and discussion section, we check that univariate and multivariate analyses failed to show COPD as a predictor of metabolic disorders and visceral adiposity in the cohort. Some confounding factors like BMI and different phenotype of COPD could explain the conclusions, what more confounding factors may be related to these results? Have you found any article where it appears?

Minor points:

1\) In the discussion section, line 23: Leone et al. instead of Leone and collegues.

Reviewer \#2: Viglino and colleagues report that they found no differences in the distribution of metabolic parameters among patients with and without COPD in a Canadian cohort. I would like to address some concerns.

Major comments:

\- The sample size is very small (263 subjects including 119 controls), also in comparison to numerous other studies on the same subject: In a recent meta-analysis (Cebron Lipovec, COPD 2016) the majority of 19 included studies had more patients than the present study. Authors should explain why the majority of CanCOLD participants were not included in the present sub-analysis and how the sub-analysis group was chosen.

\- Authors state several times that they wanted to investigate whether COPD "alters" or "predicts" the metabolic risk profile. This cannot be shown in a cross sectional analysis, but must be investigated in longitudinal and/or intervention studies. On the other hand, authors report on "prospective classification" of COPD and on a "follow-up investigation". These longitudinal data should be shown.

\- Severe forms of COPD (GOLD III and IV) are clearly underrepresented. Does this mirror the severity of the total CanCOLD population? Also, additionally to the GOLD classification the symptoms and the risk of exacerbations (Group A-D of the GOLD Guideline 2011) should be taken into account.

Minor comments:

\- Authors state several times that the chosen cohort would be representative for the general population. How was this defined and tested? Numbers vary, but epidemiologist normally demand around 40% participants of a population to call a sample "representative for the whole population".

\- Abbreviations throughout the abstract and the text should be explained at first mention (e.g. "L4-L5" in the abstract).

\- Some of the variables mentioned in the baseline characteristics are probably normally distributed (age, body-mass index, waist-hip ratio). These should be presented with mean and standard deviation instead of median and interquartile range.

\- Authors should comment on the low percentage of patients taking inhalative short- and long-acting bronchodilators.

Reviewer \#3: 1.It would have been better if the spirometry data were included in six standard items including: FEV1-FVC-FEV1/FVC-PEF-FEF25-75 and VEXt or Evol.

2\. How is sleep apnea measured?

3.Please consult with an epidemiologist for statistical analysis.

4.Please edit minor changes in English grammar.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

3 Mar 2020

2nd March, 2020

Dear Editor,

Please find enclosed the revised version of our article entitled "Metabolic profiles among COPD and controls in the CanCOLD population-based cohort".

We are grateful to the reviewers for their time and effort in evaluating our manuscript, and appreciate their comments. The following is a point-by-point response to the reviewers' comments and journal requirements.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response: This has been done accordingly

2\. Thank you for including your ethics statement:

\'All study participants provided written informed consent and the study was approved by the ethics committees of participating centres. CanCOLD(ClinicalT[rials.gov:NCT00920348](http://rials.gov:NCT00920348))

steering and scientific committees approved the sub study protocol\'

Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

Response: This has been done accordingly:

Manuscript, Methods: "The study was approved by the local ethics committee (Comité d'éthique du centre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, IRB N° 20690, Study N° 2012-1359). CanCOLD (ClinicalTrials.gov: NCT00920348) steering and scientific committees approved the sub-study protocol. All study participants signed written consent before inclusion."

3\. Please provide additional details regarding healthy participants consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was suitably informed and (2) what type you obtained (for instance, written or verbal). If your study included minors under age 18, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

Response: All study participants, controls and COPD, signed written consent. The following statement has been added:

Manuscript, Methods: "All study participants signed written consent before inclusion."

4\. We noticed you have some minor occurrence(s) of overlapping text with the following previous publication(s), which needs to be addressed:

<https://doi.org/10.2147/COPD.S168963>

<https://doi.org/10.1152/ajpendo.00505.2018>

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed.

Response: We supposed that the overlap part is the description of the visceral adipose tissue assessment in the Methods section. We used the same text as we did in previous publications since this technique is strictly identical and performed by the same team with the same tools in our study and in both previous publications cited :

"Abdominal fat distribution was assessed with L4-L5 CT scans, and images were analyzed without knowledge of the clinical status of the subjects using a specialized software (Tomovision SliceOMatic 4.3 Rev-6f software, Montreal, Quebec, Canada). The detailed method used for the images analysis has been reported \[31\]: visceral adipose tissue (VAT) area was determined by delineating the middle of the muscle wall surrounding the abdominal cavity."

We now quote both works after this part, and have made reformulation efforts to avoid strict overlap.

5\. One of the noted authors is a group or consortium CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.

Response: This has been done accordingly

6\. Thank you for stating the following in the Competing Interests section:

\"The authors have declared that no competing interests exist\"

We note that you received funding from a commercial source: Astra Zeneca Canada Ltd; Boehringer Ingelheim Canada Ltd; GlaxoSmithKline Canada Ltd; Novartis; Almirall; Merck Nycomed; Pfizer Canada Ltd; and Theratechnologies.

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Response: All funding sources (study, CanCOLD cohort) were properly cited in the "Financial disclosure" statement during the submission process. Indeed, we did not mention the individual competing interest outside the present work.

Our amended and detailed Competing Interests Statement is now available in the cover letter as requested.

 

Reviewers\' comments:

Reviewer \#1:

This article tries to find out if COPD contributes independently to development of some cardiometabolic risk factors (visceral adipose tissue, assessment of insulin resistance: HOMA-IR and lipids profile).

Major points:

1\) The study was with random population sampling, and at last it included 263 participants. As indicated in the limitations, it could be a small sample size. Is this sample representative of the general population? Why did you do only a sub-analysis restricted to individuals with an obstructive ventilatory defect?

Response: This CanCOLD sub-study has been specifically designed to evaluate whether COPD is a predictor of cardiometabolic health and to document if the determinants of cardiometabolic health are similar in COPD and in healthy subjects with normal lung function, excluding those other spirometric abnormalities such as a restrictive pattern. Some non-COPD subjects with abnormal but non-obstructive spirometric pattern were excluded. The substudy involved numerous additional examinations and follow-up, including abdominal CT scans and biological samples, which could not be obtained in all CanCOLD participating centres. Indeed, all CanCOLD participants in two CanCOPD participating centres were involved. Despite a smaller sample size than with the entire CanCOLD cohort, we expect from the random population sampling method, as opposed to convenience sampling, a cohort of COPD subjects (even non-diagnosed previously) and healthy subjects that is representative of the general population. Furthermore, the distribution of subjects characteristics in this sub-study is very similar to that of the entire CanCOLD cohort (see Labonté et al, AJRCCM 2016 194(3), 285-298), with a majority of GOLD 1 grades, few GOLD 3 or 4, and only 30% of COPD patients with previously diagnosed COPD.

Indeed, these limitations are now clearly stated in the manuscript :

"given the relatively small sample size, a lack of statistical power could be proposed to explain the absence of differences in endpoints between COPD subjects and controls. However, the similitude in the distribution of metabolic variables and obesity in the two groups studied makes this explanation unlikely. Second, the relatively small size of our otherwise well phenotyped sample could have led to a lesser representative image of the population than did the entire CanCOLD cohort. Despite this, the distribution of study participants' characteristics in this sub-study was very similar to that of the entire cohort \[51\], with a majority of subjects with GOLD 1 and few GOLD 3 and 4 COPD. Furthermore, only 30% of individuals with COPD in this sub-study were previously diagnosed with the disease, another similitude with other population-based cohorts \[52\], providing further reassurance regarding how representative the present cohort is of the general population. That said, despite all the care devoted to building a cohort of individuals representative of the general population, some biases may still be present. For example, the most fragile or diseased subjects would probably be less inclined to participate in a clinical study."

2\) In the results and discussion section, we check that univariate and multivariate analyses failed to show COPD as a predictor of metabolic disorders and visceral adiposity in the cohort. Some confounding factors like BMI and different phenotype of COPD could explain the conclusions, what more confounding factors may be related to these results? Have you found any article where it appears?

Response: ("Failed" was used in the manuscript with the meaning of "negative", not "failure"). More than explaining this conclusion, taking into account BMI and other factors related to metabolic parameters shows that COPD status per se does not seem to modify metabolic parameters. This means for us that COPD patients may have different morphological characteristics, but at identical morphological characteristics, the metabolic parameters are not modified by the presence of COPD. Furthermore, our results are consistent even in univariate analysis.

To our knowledge, the main known confounding factors of cardiometablic health were taken into account in our analyses, and were sufficient to correct an effect which is not due to COPD. Adding functional status or sedentarity scores in models (links with metabolic syndrome well described in the literature) could have been considered, but no such prospective evaluation was planned.

Minor points:

1\) In the discussion section, line 23: Leone et al. instead of Leone and colleagues.

Response: This has been corrected.

Reviewer \#2:

Viglino and colleagues report that they found no differences in the distribution of metabolic parameters among patients with and without COPD in a Canadian cohort. I would like to address some concerns.

Major comments:

1\) The sample size is very small (263 subjects including 119 controls), also in comparison to numerous other studies on the same subject: In a recent meta-analysis (Cebron Lipovec, COPD 2016) the majority of 19 included studies had more patients than the present study. Authors should explain why the majority of CanCOLD participants were not included in the present sub-analysis and how the sub-analysis group was chosen.

And:

3\) Severe forms of COPD (GOLD III and IV) are clearly underrepresented. Does this mirror the severity of the total CanCOLD population? Also, additionally to the GOLD classification the symptoms and the risk of exacerbations (Group A-D of the GOLD Guideline 2011) should be taken into account.

Response: This sub-study has been designed specifically evaluate whether COPD is a predictor of cardiometabolic health and to document if the determinants of cardiometabolic health are similar in COPD and in healthy subjects with normal lung function, excluding those other spirometric abnormalities such as a restrictive pattern.

The substudy involved numerous additional examinations and follow-up, including abdominal CT scans and biological samples, which could not be obtained in all CanCOLD participating centres. Indeed, all CanCOLD participants in two CanCOPD participating centres were involved. Despite a smaller sample size than with the entire CanCOLD cohort, we expect from the random population sampling method, as opposed to convenience sampling, a cohort of COPD subjects (even non-diagnosed previously) and healthy subjects that is representative of the general population. Furthermore, the distribution of subjects characteristics in this sub-study is very similar to that of the entire CanCOLD cohort (see Labonté et al, AJRCCM 2016 194(3), 285-298), with a majority of GOLD 1 grades, few GOLD 3 or 4, and only 30% of COPD patients with previously diagnosed COPD.

These limitations are now clearly stated in the manuscript :

"given the relatively small sample size, a lack of statistical power could be proposed to explain the absence of differences in endpoints between COPD subjects and controls. However, the similitude in the distribution of metabolic variables and obesity in the two groups studied makes this explanation unlikely. Second, the relatively small size of our otherwise well phenotyped sample could have led to a lesser representative image of the population than did the entire CanCOLD cohort. Despite this, the distribution of study participants' characteristics in this sub-study was very similar to that of the entire cohort \[51\], with a majority of subjects with GOLD 1 and few GOLD 3 and 4 COPD. Furthermore, only 30% of individuals with COPD in this sub-study were previously diagnosed with the disease, another similitude with other population-based cohorts \[52\], providing further reassurance regarding how representative the present cohort is of the general population. That said, despite all the care devoted to building a cohort of individuals representative of the general population, some biases may still be present. For example, the most fragile or diseased subjects would probably be less inclined to participate in a clinical study."

Regarding the A,B,C,D GOLD classification, the proportion of patients has been added to the table 1. The CAT scores and the A,B,C,D classification have been added in the database (supporting information).

We tested a subgroup analysis using the A,B,C, D GOLD classification instead of the dichotomy GOLD 1 vs. GOLD 2+, without modification of the results obtained. This similitude between the two analyses is likely due to the small number of patients in categories C (2.1%) and D (6.9%). For the sake of clarity of the message, we have not included these analyzes in the results.

2\) Authors state several times that they wanted to investigate whether COPD "alters" or "predicts" the metabolic risk profile. This cannot be shown in a cross sectional analysis, but must be investigated in longitudinal and/or intervention studies. On the other hand, authors report on "prospective classification" of COPD and on a "follow-up investigation". These longitudinal data should be shown.

Response: We agree that the vocabulary that was used to illustrate our interpretation of the findings was not totally clear. First, the "metabolic risk profile" is commonly admitted to describe risk factors related to metabolic disorders, not the occurrence of events.

-Prospective classification : Most studies include previously diagnosed COPD patients. The classification into COPD or Healthy was done prospectively in the CanCOLD cohort since the clinical status of the individuals was unknown at the time of study inclusion. This study design was used to build a cohort of subjects who would be representative of the general population, also capturing non-diagnosed patients. The purpose of this report was to report the cross-sectional data and not the longitudinal follow-up which is still incomplete. We agree with the reviewer that only longitudinal data could be used to infer causal relationship between the presence of COPD and cardiometabolic health. We have amended the text of the revised manuscript accordingly.

-Predicts : Although, it is possible by using mathematical models to "predict" a variable or characteristic from other characteristics of a subject at a given time, we have we changed some formulations to avoid misunderstandings :

Introduction : "In the present follow-up investigation \[...\]"

Results : "In multivariate analysis, the COPD status (or COPD 2+) did not emerge as predictors was not associated with triglyceride \>1.5 mmol/L \[...\]"

Discussion : "Univariate and multivariate analyses failed to show COPD as a predictor of showed an absence of association between COPD and metabolic disorders or visceral adiposity."

3\) Authors state several times that the chosen cohort would be representative for the general population. How was this defined and tested? Numbers vary, but epidemiologist normally demand around 40% participants of a population to call a sample "representative for the whole population".

Response: It would be extremely difficult and costly to support a study with this level of phenotyping involving 40% of its initial population. The remaining alternative is therefore random sampling, which is a unique contribution of CanCOLD. We discuss within the limits of the study a possible lack of power, but it is still difficult to question the representativeness of a random sample, especially since the characteristics of the patients are similar to those of the entire cohort (see above).

4\) Abbreviations throughout the abstract and the text should be explained at first mention (e.g. "L4-L5" in the abstract).

Response: "4th/5th lumbar vertebrae level" has been added to the first mention of L4-L5 in the manuscript.

5\) Some of the variables mentioned in the baseline characteristics are probably normally distributed (age, body-mass index, waist-hip ratio). These should be presented with mean and standard deviation instead of median and interquartile range.

Response: Only the waist-hip ratio and PEF were normally distributed in both groups (COPD and Controls) using the Kolmogorov-Smirnov test, and the same result is obtained using the Shapiro-Wilk test.

These variables are now presented with mean and 95% CI, the Table legend and the "data analysis" section have been modified accordingly.

6\) Authors should comment on the low percentage of patients taking inhalative short- and long-acting bronchodilators.

Response: As explained above, only 30% of CanCOLD COPD patients were diagnosed with the disease before the study. This point has been added in the discussion :

"Furthermore, only 30% of individuals with COPD in this sub-study were previously diagnosed with the disease, another similitude with other population-based cohorts \[52\], providing further reassurance regarding how representative the present cohort is of the general population. That said, despite all the care devoted to building a cohort of individuals representative of the general population, some biases may still be present. For example, the most fragile or diseased subjects would probably be less inclined to participate in a clinical study."

Reviewer \#3:

1\) It would have been better if the spirometry data were included in six standard items including: FEV1-FVC-FEV1/FVC-PEF-FEF25-75 and VEXt or Evol.

Response: PEF and FEF 25-75 have been added in the Table 1 accordingly, and in the database (supporting information).

The Vext being a measure of quality of the test only, it is very unusual to present it, all the spirometry being made according to standards of quality, with a new test if the value of the Vext was abnormal. Furthermore, the quality and the validity of the spirometric procedures in CanCOLD have been validated (Tan WC et al. COPD 2014;11:143-151)

2\) How is sleep apnea measured?

Response: As explained in the limitations, no systematic polysomnography was planned in the cohort ("sleep apnea another potential contributor is by far underdiagnosed in this cohort when looking at the reported prevalence."). Diagnosed sleep apnea was searched through standardized questionnaires, including the Pittsburg Sleep Quality Index (see Shorofsky M et al. Chest 2019;156:852-863, "Impaired Sleep Quality in COPD Is Associated With Exacerbations: The CanCOLD Cohort Study") and the presence of specific treatments (CPAP). Indeed, since the cohort aimed to include a representative population, it also had to include undiagnosed patients (COPD, sleep apnea), and a polysomnography would have created an intervention bias. The low proportion of sleep apnea diagnosed is representative of the general population.

We cited more clearly this point in the manuscript :

Methods : "Although no sleep studies were done in CanCOLD, the presence of sleep apnea was documented based on the use of continuous airway positive pressure (CPAP) and on standardized questionnaires, including the Pittsburg Sleep Quality Index \[31\]."

3\) Please consult with an epidemiologist for statistical analysis.

Response: We do not know if your comment concerns the editor (request for statistical revision) or our team. J. Bourbeau and D. Viglino are qualified epidemiologists, and the statistical analysis plan has been reviewed by Dr Gaétan Daigle, a professional statistician at Laval University, QC, CA.

4\) Please edit minor changes in English grammar.

Response: This version of the manuscript has been proofread for English. In the absence of specific points to help us, we hope the changes you pointed out have been made.

###### 

Submitted filename: Response to reviewers.docx

###### 

Click here for additional data file.
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Dear Dr. VIGLINO,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.
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